<div id="readability-page-1">04:43 AM EST, 01/30/2026 (MT Newswires) -- AstraZeneca ( AZN ) said early Friday it will pay $1.2 billion to CSPC Pharmaceuticals to advance multiple therapies for obesity and type 2 diabetes across eight programs.CSPC is eligible to receive development and regulatory milestones of up to $3.5 billion across all programs, AstraZeneca ( AZN ) said. It will also be eligible for further commercialisation and sales milestones as well as tiered royalties.The companies will initially progress four programs, deploying CSPC's artificial intelligence-driven peptide drug discovery platform and its proprietary LiquidGel once-monthly dosing platform technology, according to the statement.As part of the deal, AstraZeneca ( AZN ) will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight-management portfolio, it said. The company also has option to pursue future metabolic programs, leveraging CSPC's dosing platform technology, and holds rights to deploy this across internal development programs.The transaction is expected to close in Q2. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

阿斯利康将支付 12 亿美元给中科院药业，以增强其体重管理产品组合，重点关注肥胖和 2 型糖尿病的治疗。中科院药业可能在开发和监管里程碑中获得高达 35 亿美元的收益。该交易包括中科院药业每月一次注射的体重管理产品在中国以外的独家全球权利，以及未来代谢项目的选择权。预计交易将在第二季度完成

AstraZeneca to Pay $1.2 Billion Upfront to CSPC Pharmaceuticals to Expand Weight Management Portfolio

fidelity

标普生物技术 ETF - SPDR

阿斯利康

医疗业 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

美国制药 ETF - iShares

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

阿斯利康将向石药集团支付 12 亿美元的预付款，以扩展其体重管理产品组合